Trifluridine/tipiracil plus bevacizumab for third-line treatment of refractory metastatic colorectal cancer: the phase 3 randomized SUNLIGHT study

被引：0

作者：

Modest, D. P. ^{[1
]}

Tabernero, J. ^{[2
]}

Prager, G. ^{[3
]}

Fakih, M. ^{[4
]}

Ciardiello, F. ^{[5
]}

Van Cutsem, E. ^{[6
,7
]}

Elez, E. ^{[2
]}

Cruz, F. ^{[8
]}

Wyrwicz, L. ^{[9
]}

Stroyakovskiy, D. ^{[10
]}

Papai, Z. ^{[11
]}

Poureau, P. -G. ^{[12
]}

Liposits, G. ^{[13
]}

Cremolini, C. ^{[14
]}

Benhadji, K. ^{[15
]}

Bondarenko, I. ^{[16
]}

Skanji, D. ^{[17
]}

Roby, L. ^{[17
]}

Amellal, N. ^{[17
]}

Taieb, J. ^{[18
]}

机构：

[1] Charite, Hamatol Onkol & Tumorimmunol, Berlin, Germany

[2] Vall dHebron Univ Hosp & Inst Oncol VHIO, UVic UCC, IOB Quiron, Barcelona, Spain

[3] Med Univ Vienna, Dept Med 1, Vienna, Austria

[4] City Hope Comprehens Canc Ctr, Duarte, CA USA

[5] Univ Campania Luigi Vanvitelli, Dept Precis Med, Neapel, Italy

[6] Univ Hosp Leuven, Dept Digest Oncol, Herent, Belgium

[7] Katholieke Univ Leuven, Dept Digest Oncol, Herent, Belgium

[8] Nucleo Pesquisa & Ensino Rede Sao Camilo, Sao Paulo, Brazil

[9] Maria Sklodowska Curie Natl Canc Res Inst, Dept Radiotherapy & Oncol, Warsaw, Poland

[10] Moscow City Oncol Hosp 62, Moscow, Russia

[11] Duna Med Ctr, Med Oncol, Budapest, Hungary

[12] Inst Cancerol, Brest, France

[13] Univ Southern Denmark, Dept Clin Res, Odense, Denmark

[14] Univ Pisa, Dept Translat Res & New Technol, Pisa, Italy

[15] Taiho Oncol Inc, Princeton, NJ USA

[16] Dnipropetrovsk Med Acad, Dept Oncol & Med Radiol, Dnipro, Ukraine

[17] Servier Int Res Inst, Suresnes, France

[18] Univ Paris Cite, Georges Pompidou European Hosp, SIRIC CARPEM, Paris, France

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

V1019

引用

页码：157 / 158

页数：2

共 50 条

[1] Trifluridine/tipiracil plus bevacizumab for third-line treatment of refractory metastatic colorectal cancer: The phase 3 randomized SUNLIGHT study.
Tabernero, Josep
Prager, Gerald W.
Fakih, Marwan
Ciardiello, Fortunato
Van Cutsem, Eric
Elez, Elena
Cruz, Felipe Melo
Wyrwicz, Lucjan
Stroyakovskiy, Daniil
Papai, Zsuzsanna
Poureau, Pierre-Guillaume
Liposits, Gabor
Cremolini, Chiara
Bondarenko, Igor
Modest, Dominik Paul
Benhadji, Karim A.
Fougeray, Ronan
Leger, Catherine
Amellal, Nadia
Taieb, Julien
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 4 - 4
[2] Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design
Tabernero, Josep
Taieb, Julien
Prager, Gerald W.
Ciardiello, Fortunato
Fakih, Marwan
Leger, Catherine
Fougeray, Ronan
Amellal, Nadia
van Cutsem, Eric
[J]. FUTURE ONCOLOGY, 2021, 17 (16) : 1977 - 1985
[3] Cost-Effectiveness of the New Combination Trifluridine/Tipiracil Plus Bevacizumab for the Third-Line Treatment for Metastatic Colorectal Cancer in Italy
Giuliani, Jacopo
Mantoan, Beatrice
Mangiola, Daniela
Muraro, Marco
Napoli, Giuseppe
Tommasi, Marina
Fiorica, Francesco
Mandara, Marta
[J]. CLINICAL COLORECTAL CANCER, 2024, 23 (01) : 1 - 3
[4] Plain language summary of SUNLIGHT: trifluridine/tipiracil and bevacizumab for refractory metastatic colorectal cancer
Prager, Gerald W.
Taieb, Julien
Fakih, Marwan
Ciardiello, Fortunato
Cutsem, Eric Van
Elez, Elena
Wyrwicz, Lucjan
Stroyakovskiy, Daniil
Liposits, Gabor
Bondarenko, Igor
Modest, Dominik P.
Amellal, Nadia
Tabernero, Josep
[J]. FUTURE ONCOLOGY, 2024,
[5] Efficacy and safety of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil monotherapy for refractory metastatic colorectal cancer: A retrospective study
Li, Rongrong
Zhou, Hui-Jun
Zeng, De-Yu
Jiang, Shao-Feng
Liu, Wu
Liu, Zhen-yang
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[6] A Phase I dose-escalation study of third-line regorafenib with trifluridine/tipiracil in metastatic colorectal cancer
Moehler, Markus
Michel, Maurice
Stein, Alexander
Trojan, Joerg
Marquardt, Jens
Tintelnot, Joseph
Waidmann, Oliver
Weinmann, Arndt
Woerns, Marcus-Alexander
Schroeder, Helge
Maenz, Martin
Foerster, Friedrich
[J]. FUTURE ONCOLOGY, 2021, 17 (25) : 3309 - 3319
[7] Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
Prager, Gerald W.
Taieb, Julien
Fakih, Marwan
Ciardiello, Fortunato
Van Cutsem, Eric
Elez, Elena
Cruz, Felipe M.
Wyrwicz, Lucjan
Stroyakovskiy, Daniil
Papai, Zsuzsanna
Poureau, Pierre-Guillaume
Liposits, Gabor
Cremolini, Chiara
Bondarenko, Igor
Modest, Dominik P.
Benhadji, Karim A.
Amellal, Nadia
Leger, Catherine
Vidot, Loick
Tabernero, Josep
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (18): : 1657 - 1667
[8] Retrospective study of regorafenib and trifluridine/tipiracil efficacy as a third-line or later chemotherapy regimen for refractory metastatic colorectal cancer
Tanaka, Akira
Sadahiro, Sotaro
Suzuki, Toshiyuki
Okada, Kazutake
Saito, Gota
Miyakita, Hiroshi
[J]. ONCOLOGY LETTERS, 2018, 16 (05) : 6589 - 6597
[9] The TRUSTY Study: A Randomized Phase 2/3 Study of Trifluridine/Tipiracil Plus Bevacizumab Versus Irinotecan and Fluoropyrimidine Plus Bevacizumab as Second-Line Treatment in Patients With Metastatic Colorectal Cancer
不详
[J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (09) : 9 - 10
[10] Efficacy and safety of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil monotherapy for refractory metastatic colorectal cancer: a retrospective cohort study
Li, Rong-Rong
Zhou, Hui-Jun
Zeng, De-Yu
Jiang, Shao-Feng
Liu, Wu
Fruehling, Petter
Liu, Zhen-Yang
[J]. JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 15 (02) : 612 - 629

← 1 2 3 4 5 →